Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting
12 Maio 2023 - 6:06PM
Business Wire
Late-Breaking Abstract Demonstrates
Capabilities of ARCUS for Large Gene Excision In Vivo
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
gene editing company developing ARCUS®-based ex vivo allogeneic CAR
T and in vivo gene editing therapies, today announced that its
late-breaking abstract presenting preclinical in vivo gene editing
data for its PBGENE-DMD program, being developed for the potential
treatment of Duchenne muscular dystrophy (DMD), is available
through the American Society of Gene & Cell Therapy (ASGCT)
26th Annual Meeting website at
https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=15227.
An oral presentation, ARCUS-Mediated Excision of the “Hot Spot”
Region of the Human Dystrophin Gene for the Treatment of Duchenne
Muscular Dystrophy (DMD), will be presented as part of the
Late-breaking Abstracts 2 Session on May 19, 2023.
About ARCUS ARCUS is a proprietary genome editing
technology discovered and developed by scientists at Precision
BioSciences. It uses sequence-specific DNA-cutting enzymes, or
nucleases, that are designed to either insert (knock-in), excise
(knock-out), or repair DNA of living cells and organisms. ARCUS is
based on a naturally occurring genome editing enzyme, I-CreI, that
evolved in the algae Chlamydomonas reinhardtii to make highly
specific cuts in cellular DNA and stimulate gene insertion at the
cut site by homologous recombination. Precision's platform and
products are protected by a comprehensive portfolio including
nearly 100 patents to date.
About DMD DMD is a genetic disorder associated with
mutations in the dystrophin gene that prevent production of the
dystrophin protein. Dystrophin stabilizes the cell membrane during
muscle contraction to prevent damage, and the absence of intact
dystrophin protein leads to inflammation, fibrosis, and progressive
loss of muscle function and mass. Over time, children with DMD will
develop problems walking and breathing, eventually leading to death
in the second or third decade of life due to progressive
cardiomyopathy and respiratory insufficiency. DMD occurs in 1 in
3,500 to 5,000 male births, and currently there are limited
approved therapies available for patients.
About Precision BioSciences, Inc. Precision BioSciences,
Inc. is a clinical stage biotechnology company dedicated to
improving life (DTIL) with its novel and proprietary ARCUS® genome
editing platform. ARCUS is a highly precise and versatile genome
editing platform that was designed with therapeutic safety,
delivery, and control in mind. Using ARCUS, the Company’s pipeline
consists of several in vivo gene editing candidates designed to
cure genetic and infectious diseases where no adequate treatments
exist and multiple ex vivo clinical candidates. For more
information about Precision BioSciences, please visit
www.precisionbiosciences.com.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including,
without limitation, statements regarding expected conference
participation and disclosure of preclinical data, the clinical
development, nomination, and goals of our PBGENE-DMD program, and
therapeutic potential of an ARCUS gene editing approach for the
treatment of DMD. In some cases, you can identify forward-looking
statements by terms such as “aim,” “anticipate,” “approach,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look,” “may,” “mission,” “plan,” “possible,”
“potential,” “predict,” “project,” “pursue,” “should,” “target,”
“will,” “would,” or the negative thereof and similar words and
expressions.
Forward-looking statements are based on management’s current
expectations, beliefs and assumptions and on information currently
available to us. Such statements are neither promises nor
guarantees, but involve a number of known and unknown risks,
uncertainties and assumptions, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various important factors, including, but not
limited to, the important factors discussed under the caption “Risk
Factors” in our Quarterly Report on Form 10-Q for the quarterly
period ended March 31, 2023, as any such factors may be updated
from time to time in our other filings with the SEC, which are
accessible on the SEC’s website at www.sec.gov and the Investors
page of our website under SEC Filings at
investor.precisionbiosciences.com.
All forward-looking statements speak only as of the date of this
press release and, except as required by applicable law, we have no
obligation to update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230512005427/en/
Investor and Media Contact: Mei Burris Director, Investor
Relations and Finance Mei.Burris@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024